Edesa Biotech Stock Analysis
| EDSA Stock | USD 1.17 0.06 4.88% |
Edesa Biotech holds a debt-to-equity ratio of 0.003. With a high degree of financial leverage come high-interest payments, which usually reduce Edesa Biotech's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Edesa Biotech's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Edesa Biotech's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Edesa Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Edesa Biotech's stakeholders.
For most companies, including Edesa Biotech, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Edesa Biotech, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Edesa Biotech's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Given that Edesa Biotech's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Edesa Biotech is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Edesa Biotech to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Edesa Biotech is said to be less leveraged. If creditors hold a majority of Edesa Biotech's assets, the Company is said to be highly leveraged.
Edesa Biotech is overvalued with Real Value of 1.14 and Hype Value of 1.23. The main objective of Edesa Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Edesa Biotech is worth, separate from its market price. There are two main types of Edesa Biotech's stock analysis: fundamental analysis and technical analysis.
The Edesa Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Edesa Biotech's ongoing operational relationships across important fundamental and technical indicators.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.Edesa Stock Analysis Notes
About 17.0% of the company shares are held by company insiders. The book value of Edesa Biotech was currently reported as 0.45. The company recorded a loss per share of 1.27. Edesa Biotech last dividend was issued on the 10th of June 2019. The entity had 1:7 split on the 11th of October 2023. Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Edesa Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people. To learn more about Edesa Biotech call MD FRCPC at 289 800 9600 or check out https://www.edesabiotech.com.Edesa Biotech Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Edesa Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Edesa Biotech or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Edesa Biotech generated a negative expected return over the last 90 days | |
| Edesa Biotech may become a speculative penny stock | |
| Edesa Biotech has high historical volatility and very poor performance | |
| Edesa Biotech has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.19 M) with profit before overhead, payroll, taxes, and interest of 311.2 K. | |
| Edesa Biotech currently holds about 12.81 M in cash with (7.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.83. | |
| Roughly 17.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program |
Edesa Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.25 M.Technical Drivers
As of the 30th of January, Edesa Biotech shows the Standard Deviation of 3.63, variance of 13.18, and Mean Deviation of 2.43. Edesa Biotech technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Edesa Biotech Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Edesa Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Edesa Biotech. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Edesa Biotech Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edesa Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edesa Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edesa Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edesa Biotech Outstanding Bonds
Edesa Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edesa Biotech uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edesa bonds can be classified according to their maturity, which is the date when Edesa Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Edesa Biotech Predictive Daily Indicators
Edesa Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Edesa Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 34908.42 | |||
| Daily Balance Of Power | (0.38) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 1.17 | |||
| Day Typical Price | 1.17 | |||
| Price Action Indicator | (0.03) | |||
| Period Momentum Indicator | (0.06) | |||
| Relative Strength Index | 32.09 |
Edesa Biotech Forecast Models
Edesa Biotech's time-series forecasting models are one of many Edesa Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Edesa Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Edesa Biotech Debt to Cash Allocation
As Edesa Biotech follows its natural business cycle, the capital allocation decisions will not magically go away. Edesa Biotech's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Edesa Biotech currently holds 1.21 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Edesa Biotech has a current ratio of 2.63, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Edesa Biotech's use of debt, we should always consider it together with its cash and equity.Edesa Biotech Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Edesa Biotech's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Edesa Biotech, which in turn will lower the firm's financial flexibility.Edesa Biotech Corporate Bonds Issued
Most Edesa bonds can be classified according to their maturity, which is the date when Edesa Biotech has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
About Edesa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Edesa Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Edesa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Edesa Biotech. By using and applying Edesa Stock analysis, traders can create a robust methodology for identifying Edesa entry and exit points for their positions.
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada. Edesa Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 16 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Edesa Biotech to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Stock Screener Now
Stock ScreenerFind equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
| All Next | Launch Module |
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |